logo image
search icon
Alpha 1 Lung Disease Market

Alpha 1 Lung Disease Market Size, Share & Trends Analysis Report By Disease Type (Alpha-1 Antitrypsin Deficiency, Chronic Obstructive Pulmonary Disease (COPD), Pulmonary Fibrosis, Bronchiectasis, Others), By Treatment Type (Augmentation Therapy, Bronchodilators, Corticosteroids, Oxygen Therapy, Lung Transplantation, Others), By Route of Administration, By Distribution Channel, By End User, By Region, And By Segment Forecasts, 2023-2031.

Report ID : 2274 | Published : 2023-12-13 | Pages: 180 | Format: PDF/EXCEL

Alpha 1 Lung Disease Market Size is valued at USD 4.13 Billion in 2022 and is predicted to reach USD 19.93 Billion by the year 2031 at a 19.33% CAGR during the forecast period for 2023-2031.

Alpha 1 Lung Disease Market

Alpha-1 Antitrypsin Deficiency is a genetic disorder in which the body does not make enough of a protein known as alpha-1 antitrypsin. This protein is very important for keeping the lungs safe from damage caused by inflammation. People who don't get enough of this protein are more likely to get lung illnesses like emphysema and chronic obstructive pulmonary disease (COPD). Some people who don't have enough Alpha-1 Antitrypsin may also have trouble with their liver. The main goal of treatment is to control the symptoms; in some cases, augmentation therapy may be used to restore the missing protein. Adults usually have pulmonary difficulties, and both adults and children can have skin problems. In paediatric cases of AATD, liver illness, rather than COPD, is the most common form of the disease.

However, during the pandemic, the global supply chain for medications and medical supplies encountered difficulties. This could have hampered Alpha-1 sufferers' access to drugs and treatments. The pandemic may have slowed ongoing clinical trials and research on Alpha-1 Antitrypsin Deficiency. This could have an impact on the timetables for developing and approving novel treatments.

Competitive Landscape

Some Major Key Players In The Alpha 1 Lung Disease Market:

  • AstraZeneca
  • Boehringer Ingelheim
  • Roche
  • Novartis
  • Pfizer
  • Merck
  • Bristol-Myers Squibb
  • Takeda Pharmaceutical
  • CSL Behring
  • Vertex Pharmaceuticals
  • Amgen
  • Sanofi
  • GlaxoSmithKline
  • Gilead Sciences
  • Eli Lilly
  • AbbVie,
  • Johnson & Johnson
  • Teva Pharmaceutical
  • Audentes Therapeutics
  • Regeneron Pharmaceuticals
  • LFB Biomedicaments
  • Grifols
  • Kamada Ltd
  • Others

Market Segmentation:

The Alpha 1 Lung Disease Market is segmented according to disease type, treatment type, route of administration, distribution channel, and end-user. As per the disease type, the market is segmented as Alpha-1 Antitrypsin Deficiency, Chronic Obstructive Pulmonary Disease (COPD), Pulmonary Fibrosis, Bronchiectasis, and Others. The treatment type segment includes Augmentation Therapy, Bronchodilators, Corticosteroids, Oxygen Therapy, Lung Transplantation, Others. The route of administration segment consists of Inhalation, Injectable, and Oral. The distribution channel segment includes Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. The end-user segment includes Hospitals, Homecare, specialty Clinics, and Others.

Based On Disease Type, The Chronic Obstructive Pulmonary Disease (COPD) Segment Is Accounted As A Major Contributor In The Alpha 1 Lung Disease Market. 

The Chronic Obstructive Pulmonary Disease (COPD) category is expected to hold a major share in the global Alpha 1 Lung Disease Market in 2022. Alpha-1 Antitrypsin Deficiency (Alpha-1) is a hereditary condition that can result in chronic obstructive pulmonary disease (COPD). COPD is a progressive lung illness characterized by airflow limitation, and those with Alpha-1 are more likely to develop it. Ongoing COPD research and development activities, especially those linked with Alpha-1, can potentially lead to the development of new and more effective treatment alternatives.

The Hospital Segment Witnessed A Rapid Expansion.

The hospital segment is expected to grow at a rapid rate in the global Alpha 1 Lung Disease Market. As awareness rises and diagnostic skills improve, there may be an increase in patient admissions to hospitals for Alpha-1 Lung Disease diagnosis and care. Hospitals are critical in providing diagnostic services for genetic abnormalities such as Alpha-1. In this setting, demand for genetic testing and diagnostic services may fuel growth. Hospitals provide both inpatient and outpatient care, ranging from urgent interventions to long-term therapy for people with Alpha-1-related lung illnesses.

In The Region, The North America Alpha 1 Lung Disease Market Holds A Significant Revenue Share.

The North America Alpha 1 Lung Disease Market is expected to record the maximum market revenue share in the near future. The Alpha-1 Lung Disease market drivers in North America are influenced by a variety of factors, including healthcare infrastructure, research and development, patient awareness, and regulatory considerations. The Europe alpha-1 antitrypsin deficiency disease market is also predicted to grow rapidly. Efforts to raise awareness about genetic abnormalities and uncommon diseases, such as Alpha-1 Antitrypsin Deficiency, have the potential to lead to earlier discovery and diagnosis in the European community. Growth and development in healthcare infrastructure across the European region can contribute to improved access to diagnostic services and specialized treatment for Alpha-1 Lung Disease.

Recent Developments:

  • In May 2023, Kamada Pharmaceuticals announced Glassia's Swiss commercial approval for the treatment of alpha-1 antitrypsin insufficiency. Swissmedic has approved Glassia [Alpha-1 Proteinase Inhibitor (Human)] for prolonged augmentation and maintenance therapy in patients with clinically evident emphysema due to severe familial alpha-1 antitrypsin deficiency illness.

Alpha 1 Lung Disease Market Report Scope

Report Attribute

Specifications

Market Size Value In 2022

USD 4.13 Billion

Revenue Forecast In 2031

USD 19.93 Billion

Growth Rate CAGR

CAGR of 19.33 % from 2023 to 2031

Quantitative Units

Representation of revenue in US$ Million and CAGR from 2023 to 2031

Historic Year

2019 to 2022

Forecast Year

2023-2031

Report Coverage

The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends

Segments Covered

By Disease Type, By Treatment Type, By Route of Administration, By Distribution Channel, By End User

Regional Scope

North America; Europe; Asia Pacific; Latin America; Middle East & Africa

Country Scope

U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea

Competitive Landscape

AstraZeneca, Boehringer Ingelheim, Roche, Novartis, Pfizer, Merck, Bristol-Myers Squibb, Takeda Pharmaceutical, CSL Behring, Vertex Pharmaceuticals, Amgen, Sanofi, GlaxoSmithKline, Gilead Sciences, Eli Lilly, AbbVie, Johnson & Johnson, Teva Pharmaceutical, Audentes Therapeutics, Regeneron Pharmaceuticals, LFB Biomedicaments, Grifols, Kamada Ltd, and Others

Customization Scope

Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape.

Pricing And Available Payment Methods

Explore pricing alternatives that are customized to your particular study requirements.

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Alpha 1 Lung Disease Market Snapshot

Chapter 4. Global Alpha 1 Lung Disease Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Investment and Funding Analysis

4.6. Industry Analysis – Porter’s Five Forces Analysis

4.7. Competitive Landscape & Market Share Analysis

4.8. Impact of Covid-19 Analysis

Chapter 5. Market Segmentation 1: By Disease Type Estimates & Trend Analysis

5.1. By Disease Type, & Market Share, 2019 & 2031

5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2023 to 2031 for the following By Disease Type:

5.2.1. Alpha-1 Antitrypsin Deficiency

5.2.2. Chronic Obstructive Pulmonary Disease (COPD)

5.2.3. Pulmonary Fibrosis

5.2.4. Bronchiectasis

5.2.5. Others

Chapter 6. Market Segmentation 2: By Treatment Type Estimates & Trend Analysis

6.1. By Treatment Type & Market Share, 2019 & 2031

6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2023 to 2031 for the following By Treatment Type:

6.2.1. Augmentation Therapy

6.2.2. Bronchodilators

6.2.3. Corticosteroids

6.2.4. Oxygen Therapy

6.2.5. Lung Transplantation

6.2.6. Others

Chapter 7. Market Segmentation 3: By Route of Administration Estimates & Trend Analysis

7.1. By Route of Administration & Market Share, 2019 & 2031

7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2023 to 2031 for the following By Route of Administration:

7.2.1. Inhalation

7.2.2. Injectable

7.2.3. Oral

Chapter 8. Market Segmentation 4: By Distribution Channel Estimates & Trend Analysis

8.1. By Distribution Channel & Market Share, 2019 & 2031

8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2023 to 2031 for the following By Distribution Channel:

8.2.1. Hospital Pharmacies

8.2.2. Retail Pharmacies

8.2.3. Online Pharmacies

Chapter 9. Market Segmentation 5: By End-Users Estimates & Trend Analysis

9.1. By End-Users & Market Share, 2019 & 2031

9.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2023 to 2031 for the following By End-Users:

9.2.1. Hospitals

9.2.2. Homecare

9.2.3. Specialty Clinics

9.2.4. Others

Chapter 10. Alpha 1 Lung Disease Market Segmentation 6: Regional Estimates & Trend Analysis

10.1. North America

10.1.1. North America Alpha 1 Lung Disease Market revenue (US$ Million) estimates and forecasts By Disease Type, 2023-2031

10.1.2. North America Alpha 1 Lung Disease Market revenue (US$ Million) estimates and forecasts By Treatment Type, 2023-2031

10.1.3. North America Alpha 1 Lung Disease Market revenue (US$ Million) estimates and forecasts By Route of Administration, 2023-2031

10.1.4. North America Alpha 1 Lung Disease Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2023-2031

10.1.5. North America Alpha 1 Lung Disease Market revenue (US$ Million) estimates and forecasts By End-Users, 2023-2031

10.1.6. North America Alpha 1 Lung Disease Market revenue (US$ Million) estimates and forecasts by country, 2023-2031

10.2. Europe

10.2.1. Europe Alpha 1 Lung Disease Market revenue (US$ Million) By Disease Type, 2023-2031

10.2.2. Europe Alpha 1 Lung Disease Market revenue (US$ Million) By Treatment Type, 2023-2031

10.2.3. Europe Alpha 1 Lung Disease Market revenue (US$ Million) By Route of Administration, 2023-2031

10.2.4. Europe Alpha 1 Lung Disease Market revenue (US$ Million) By Distribution Channel, 2023-2031

10.2.5. Europe Alpha 1 Lung Disease Market revenue (US$ Million) By End-Users, 2023-2031

10.2.6. Europe Alpha 1 Lung Disease Market revenue (US$ Million) by country, 2023-2031

10.3. Asia Pacific

10.3.1. Asia Pacific Alpha 1 Lung Disease Market revenue (US$ Million) By Disease Type, 2023-2031

10.3.2. Asia Pacific Alpha 1 Lung Disease Market revenue (US$ Million) By Treatment Type, 2023-2031

10.3.3. Asia Pacific Alpha 1 Lung Disease Market revenue (US$ Million) By Route of Administration, 2023-2031

10.3.4. Asia Pacific Alpha 1 Lung Disease Market revenue (US$ Million) By Distribution Channel, 2023-2031

10.3.5. Asia Pacific Alpha 1 Lung Disease Market revenue (US$ Million) By End-Users, 2023-2031

10.3.6. Asia Pacific Alpha 1 Lung Disease Market revenue (US$ Million) by country, 2023-2031

10.4. Latin America

10.4.1. Latin America Alpha 1 Lung Disease Market revenue (US$ Million) By Disease Type, (US$ Million) 2023-2031

10.4.2. Latin America Alpha 1 Lung Disease Market revenue (US$ Million) By Treatment Type, (US$ Million) 2023-2031

10.4.3. Latin America Alpha 1 Lung Disease Market revenue (US$ Million) By Route of Administration, (US$ Million) 2023-2031

10.4.4. Latin America Alpha 1 Lung Disease Market revenue (US$ Million) By Distribution Channel, (US$ Million) 2023-2031

10.4.5. Latin America Alpha 1 Lung Disease Market revenue (US$ Million) By End-Users, (US$ Million) 2023-2031

10.4.6. Latin America Alpha 1 Lung Disease Market revenue (US$ Million) by country, 2023-2031

10.5. Middle East & Africa

10.5.1. Middle East & Africa Alpha 1 Lung Disease Market revenue (US$ Million) By Disease Type, (US$ Million) 2023-2031

10.5.2. Middle East & Africa Alpha 1 Lung Disease Market revenue (US$ Million) By Treatment Type, (US$ Million) 2023-2031

10.5.3. Middle East & Africa Alpha 1 Lung Disease Market revenue (US$ Million) By Route of Administration, (US$ Million) 2023-2031

10.5.4. Middle East & Africa Alpha 1 Lung Disease Market revenue (US$ Million) By Distribution Channel, (US$ Million) 2023-2031

10.5.5. Middle East & Africa Alpha 1 Lung Disease Market revenue (US$ Million) By End-Users, (US$ Million) 2023-2031

10.5.6. Middle East & Africa Alpha 1 Lung Disease Market revenue (US$ Million) by country, 2023-2031

Chapter 11. Competitive Landscape

11.1. Major Mergers and Acquisitions/Strategic Alliances

11.2. Company Profiles

11.2.1. AstraZeneca,

11.2.2. Boehringer Ingelheim,

11.2.3. Roche ,

11.2.4. Novartis,

11.2.5. Pfizer,

11.2.6. Merck,

11.2.7. Bristol-Myers Squibb,

11.2.8. Takeda Pharmaceutical,

11.2.9. CSL Behring,

11.2.10. Vertex Pharmaceuticals,

11.2.11. Amgen,

11.2.12. Sanofi,

11.2.13. GlaxoSmithKline,

11.2.14. Gilead Sciences ,

11.2.15. Eli Lilly,

11.2.16. AbbVie,

11.2.17. Johnson & Johnson,

11.2.18. Teva Pharmaceutical,

11.2.19. Audentes Therapeutics,

11.2.20. Regeneron Pharmaceuticals

11.2.21. LFB Biomedicaments

11.2.22. Grifols

11.2.23. Kamada Ltd

11.2.24. Others

Segmentation of Alpha 1 Lung Disease Market-

Alpha 1 Lung Disease Market By Disease Type-

  • Alpha-1 Antitrypsin Deficiency
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Pulmonary Fibrosis
  • Bronchiectasis
  • Others

Alpha 1 Lung Disease Market Seg

Alpha 1 Lung Disease Market By Treatment Type-

  • Augmentation Therapy
  • Bronchodilators
  • Corticosteroids
  • Oxygen Therapy
  • Lung Transplantation
  • Others

Alpha 1 Lung Disease Market By Route of Administration-

  • Inhalation
  • Injectable
  • Oral

Alpha 1 Lung Disease Market By Distribution Channel-

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Alpha 1 Lung Disease Market By End User-

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

Alpha 1 Lung Disease Market By Region-

North America-

  • The US
  • Canada
  • Mexico

Europe-

  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia-Pacific-

  • China
  • Japan
  • India
  • South Korea
  • South East Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Argentina
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa
  • Rest of Middle East and Africa

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

user icon
office icon
mail icon
call icon

This website is secure, and we do not share your personal information with any third party. Privacy Policy

Need Customization
Need specific information/chapter from the report of the custom data table, graph or complete report? Tell us more.

Frequently Asked Questions

How big is the Alpha 1 Lung Disease Market ?

Alpha 1 Lung Disease Market expected to grow at a 19.33% CAGR during the forecast period for 2023-2031.

Teva Pharmaceutical, Audentes Therapeutics, Regeneron Pharmaceuticals, LFB Biomedicaments, Grifols, Kamada Ltd, and Others

Our Clients

  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo

Media Citations

  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo

Growth opportunities and latent adjacency in Pharmaceuticals

Select Licence Type
$4456
$7786
$10000
$1200
Get Your GTM Strategy

Navigate market entry with channel selection, launch strategy & timeline, and pricing model support.

Equip yourself with the insights needed to develop a winning go-to-market strategy

Get real-time updates and joint control over project direction with our collaborative approach